Post by CTIN (Clinical Trials Information Network)

Rare diseases are often grouped into one category, but the research landscape tells a much more uneven story. In Spain, clinical trial activity is clearly concentrated around a limited number of indications, with plasma cell myeloma, acute myeloid leukaemia, and myelodysplastic syndrome leading the ranking. At the same time, many other rare diseases remain represented by far fewer trials. Why does this matter? Because for patients, access to innovation depends not only on scientific progress itself, but on whether research is happening in their disease area at all. Looking at the data this way helps reveal where momentum is strongest, where the gaps remain, and where future clinical research could make an even bigger difference. What do you think drives this concentration most: feasibility, funding, site readiness, or unmet need? 🌍 We are CTIN → Clinical Trials Information Network 𝐖𝐞 𝐛𝐫𝐢𝐝𝐠𝐞 𝐄𝐮𝐫𝐨𝐩𝐞’𝐬 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐞𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 🔍 Follow for clinical research market insights 🤝 Share to support our mission #DataInsights #RareDiseases #Spain Pankaj Patel Heather P. Gonzalo Linares Michele Oshman Cynthia (Cyndi) Grossman